series-a
Stage
1
Investors
About
T-Therapeutics develops bispecific T cell engagers leveraging a proprietary TCR-CD3 platform to target previously undruggable intracellular antigens, focusing on therapies for cancer and autoimmune diseases.
Explore T-Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.